Epstein-Barr virus infection transforms CD25+ B cells into antibody-secreting cells in rheumatoid arthritis patients.

Item

http://www.wikidata.org/entity/Q42284576

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Epstein-Barr virus infection t ...... rheumatoid arthritis patients.

@en

Epstein-Barr virus infection t ...... rheumatoid arthritis patients.

@nl

type

Item

label

Epstein-Barr virus infection t ...... rheumatoid arthritis patients.

@en

Epstein-Barr virus infection t ...... rheumatoid arthritis patients.

@nl

prefLabel

Epstein-Barr virus infection t ...... rheumatoid arthritis patients.

@en

Epstein-Barr virus infection t ...... rheumatoid arthritis patients.

@nl

P1476

Epstein-Barr virus infection t ...... rheumatoid arthritis patients.

@en

P2093

Maria I Bokarewa

http://www.w3.org/2001/XMLSchema#string

Maria Rehnberg

http://www.w3.org/2001/XMLSchema#string

Mikael Brisslert

http://www.w3.org/2001/XMLSchema#string

P2860

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients

Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study.

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.

Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment.

The rheumatoid arthritis HLA-DRB1 shared epitope.

Epstein-Barr virus in bone marrow of rheumatoid arthritis patients predicts response to rituximab treatment.

The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis.

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab'

Disturbance of the Epstein-Barr virus-host balance in rheumatoid arthritis patients: a quantitative study.

P304

421-429

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/IMM.12151

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

140

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23844744

http://www.w3.org/2001/XMLSchema#string

P921

Epstein–Barr virus

P932

3839646

http://www.w3.org/2001/XMLSchema#string